Literature DB >> 34796974

Sensorimotor outcomes in adrenomyeloneuropathy show significant disease progression.

Jennifer L Keller1, Ani Eloyan2, Gerald V Raymond1,3,4, Ali Fatemi1,4, Kathleen M Zackowski1,4,5.   

Abstract

Current outcomes used to evaluate adrenomyeloneuropathy are limited by rater bias, not sensitive to preclinical changes, and require years to decades to detect disease progression. Quantitative outcomes are needed that detect meaningful change in a short time period over a broad range of disability. The study aim was to track sensorimotor outcomes in adults with adrenomyeloneuropathy and evaluate differences in progression between men and women. This prospective observational cohort study analyzes data collected annually in the Phase III study of adults with adrenomyeloneuropathy. Outcomes include postural sway in four static standing conditions, great-toe vibration, hip strength, walking velocity, timed up-and-go, and 6-minute walk distance. Linear mixed model analysis was used to detect change in the outcomes in 2 years, correcting for age, sex, disability, symptom duration, and treatment across the cohort. Modeling was repeated for each sex to evaluate differences. Power computations were carried out by sex and for the full dataset. Sixty-one men and 87 women participated. Average age, 46 ± 12 years; Expanded Disability Status Scale, 3 (1-6.5); symptom duration, 10.8 ± 9.4 years. The cohort showed significant worsening in all standing conditions (P < .001), sensation (P = .0223) and strength (P = .001); but more stability in walking with only velocity (P < .0337) significantly declining. For each sex, postural sway declines significantly in all conditions (P < .01) except for eyes closed feet together for women. Strength declines significantly by sex for hip flexion (P < .03). Sex-specific significant decline is seen in walking (velocity P = .0276; distance P = .0072) for men only. Quantitative measures of postural sway, sensation strength, and walking are effective measures of adrenomyeloneuropathy progression in 2 years.
© 2021 SSIEM.

Entities:  

Keywords:  balance; biomarkers; disease progression; leukodystrophy; myelopathy; peroxisomal disorder

Mesh:

Year:  2021        PMID: 34796974      PMCID: PMC8987487          DOI: 10.1002/jimd.12457

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  25 in total

1.  Longitudinal relationships among posturography and gait measures in multiple sclerosis.

Authors:  Nora E Fritz; Scott D Newsome; Ani Eloyan; Rhul Evans R Marasigan; Peter A Calabresi; Kathleen M Zackowski
Journal:  Neurology       Date:  2015-04-15       Impact factor: 9.910

2.  Balance deficit with opened or closed eyes reveals involvement of different structures of the central nervous system in multiple sclerosis.

Authors:  Luca Prosperini; Nikolaos Petsas; Eytan Raz; Emilia Sbardella; Francesca Tona; Chiara Rosa Mancinelli; Carlo Pozzilli; Patrizia Pantano
Journal:  Mult Scler       Date:  2013-06-11       Impact factor: 6.312

3.  Improving walking assessment in subjects with an incomplete spinal cord injury: responsiveness.

Authors:  H J A van Hedel; M Wirz; A Curt
Journal:  Spinal Cord       Date:  2005-11-22       Impact factor: 2.772

4.  Responsiveness of physical function outcomes following physiotherapy intervention for osteoarthritis of the knee: an outcome comparison study.

Authors:  Helen P French; Martina Fitzpatrick; Oliver FitzGerald
Journal:  Physiotherapy       Date:  2010-05-04       Impact factor: 3.358

5.  Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy.

Authors:  B M van Geel; L Bezman; D J Loes; H W Moser; G V Raymond
Journal:  Ann Neurol       Date:  2001-02       Impact factor: 10.422

6.  Clinical evaluation of childhood cerebral adrenoleukodystrophy with balint's symptoms.

Authors:  Kazuo Kubota; Hiroki Kawai; Shigeo Takashima; Takayoshi Shimohata; Mika Otsuki; Hidenori Ohnishi; Nobuyuki Shimozawa
Journal:  Brain Dev       Date:  2020-12-10       Impact factor: 1.961

7.  The 6-min walking distance: long-term follow up in patients with COPD.

Authors:  C Casanova; C G Cote; J M Marin; J P de Torres; A Aguirre-Jaime; R Mendez; L Dordelly; B R Celli
Journal:  Eur Respir J       Date:  2006-11-15       Impact factor: 16.671

8.  Postural sway as a marker of progression in Parkinson's disease: a pilot longitudinal study.

Authors:  Martina Mancini; Patricia Carlson-Kuhta; Cris Zampieri; John G Nutt; Lorenzo Chiari; Fay B Horak
Journal:  Gait Posture       Date:  2012-06-29       Impact factor: 2.840

9.  Falls in Parkinson's Disease Subtypes: Risk Factors, Locations and Circumstances.

Authors:  Paulo H S Pelicioni; Jasmine C Menant; Mark D Latt; Stephen R Lord
Journal:  Int J Environ Res Public Health       Date:  2019-06-23       Impact factor: 3.390

Review 10.  X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies.

Authors:  Bela R Turk; Christiane Theda; Ali Fatemi; Ann B Moser
Journal:  Int J Dev Neurosci       Date:  2020-01-26       Impact factor: 2.457

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.